데스모이드 종양 시장 : 약제 유형별, 유통 채널별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Desmoid Tumors Market size was valued at US$ 2,965.91 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.

Desmoid tumors are rare non-cancerous (benign) tumors that form from connective tissue cells, typically in the fascia, which surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means that they can grow and invade nearby structures but do not spread to other parts of the body like traditional cancer.

Desmoid Tumors Market- Market Dynamics

O Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market

Rising cancer rates are expected to drive future growth in the desmoid tumor market. Cancer is a group of disorders characterized by the body's abnormal cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs, causing damage. The rising number of cancer cases worldwide has increased the demand for effective and advanced chemotherapeutic agents, which has a positive impact on the desmoid tumor market. For instance, in May 2024, according to the National Cancer Institute, a federal government agency based in the United States In 2024, an estimated 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected due to the disease. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide. By 2040, the annual number of new cancer cases is expected to reach 29.9 million, with 15.3 million cancer-related deaths. As a result, rising cancer rates are driving the growth of the desmoid tumor market.

Desmoid Tumors Market- Key Insights

v As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.20% over the forecast period (2025-2032)

v Based on Drug Type segmentation, the chemotherapy segment is the largest in the global market in 2025

v Based on Distribution channel segmentation, the hospital pharmacies segment is anticipated to hold the majority of the global market.

v On the basis of region, North America was the leading revenue generator in 2024

Desmoid Tumors Market- Segmentation Analysis:

The Global Desmoid Tumors Market is segmented on the basis of Drug Type, Distribution channel, and Region.

The market is divided into five categories based on Drug Type: Non-steroidal anti-inflammatory drugs (NSAIDs), Chemotherapy, Targeted Therapy, Hormone Therapy and Others. The chemotherapy segment is the largest in the global market in 2025, and it is expected to continue to dominate the market during the forecast period. Chemotherapy, while traditionally associated with systemic side effects, remains an important treatment option, particularly for aggressive or inoperable tumors. Combination drug regimens tailored to individual patient needs have increased efficacy and tolerability. Furthermore, ongoing research into new chemotherapeutic agents with better safety profiles is expected to fuel growth in this segment. Despite its challenges, chemotherapy is still an important part of the treatment arsenal.

The market is divided into three categories based on Distribution channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is expected to account for the majority of the global market during the forecast period. Hospital pharmacies are an important distribution channel for desmoid tumor treatments because they have direct access to patients receiving treatment in healthcare facilities. These pharmacies ensure the availability of essential medications and serve as a vital link between healthcare providers and patients. Their role in managing medication supply and offering counseling services is critical to the overall treatment process.

Desmoid Tumors Market- Geographical Insights

North America is the largest regional segment in the global desmoid tumors market, and it is expected to maintain its lead position during the forecast period. Rising healthcare expenditure, rapid adoption of technological advancements, growing awareness, and rising prevalence of desmoid tumors in North America all contribute to the market's growth. Imaging advancements, such as MRI and CT scans, have improved the ability to detect and locate desmoid tumors.

The Asia-Pacific region is expected to have the highest CAGR in the global market over the forecast period. The growing patient population, increased healthcare investments and infrastructure development, and increased awareness of rare diseases and access to healthcare are the primary drivers of the desmoid tumors market in Asia-Pacific.

Desmoid Tumors Market- Competitive Landscape:

The desmoid tumors market is competitive, with pharmaceutical companies and research institutions all working to develop effective treatment options. Key players include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, and Amneal Pharmaceuticals LLC, which has participated in clinical trials for targeted therapies. Smaller biotech firms and academic institutions focused on innovative research and development contribute to the market as well. Competition is driven by the need to improve treatment outcomes, reduce side effects, and meet patients' unmet medical needs. This includes both the development of new therapies, such as targeted drugs and immunotherapies, and the enhancement of existing treatments. Regulatory approvals, clinical trial results, and patentability all have an impact on the competitive environment.

Recent Developments:

v In August, 2023, Horizon Therapeutics Plc has announced the launch of Krystexxa(R) (PEGylated brentuximab vedotin) for injection in the United States for the treatment of adult patients with unresectable or recurrent locally advanced or metastatic soft tissue sarcoma (STS) who have previously received anthracycline-containing chemotherapy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DESMOID TUMORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• O Horizon Therapeutics Plc
• O Strides Pharma Science Limited
• O Teva Pharmaceutical Industries Ltd
• O Amneal Pharmaceuticals LLC
• O Hikma Pharmaceuticals PLC
• O Natco Pharma Ltd
• O Lupin, Zydus Lifesciences
• O Mylan N.V.
• O Assertio Holdings, Inc.
• O Mayne Pharma Group Limited
• O Alembic Pharmaceuticals Limited, Aprazer
• O Ayala Pharmaceuticals
• O SpringWorks Therapeutics, Inc
• O Iterion Therapeutics
• O Novartis AG
• O Apotex Inc.
• O Bayer AG
• O Sun Pharmaceutical Industries Ltd
• O Dr. Reddy's Laboratories Ltd
• O Endo International plc
• O Abbott
• O Getwell Pharmaceuticals
• O Others

GLOBAL DESMOID TUMORS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

• O Non-steroidal anti-inflammatory drugs(NSAIDs)
• O Chemotherapy
• O Targeted Therapy
• O Hormone Therapy
• O Others

GLOBAL DESMOID TUMORS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

• O Hospital Pharmacies
• O Retail Pharmacies
• O Online Pharmacies

GLOBAL DESMOID TUMORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• O North America
• U.S.
• Canada
• O Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe
• O Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC
• O Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• O The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Desmoid Tumors Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Desmoid Tumors Market Snippet by Drug Type
  • 2.1.2. Desmoid Tumors Market Snippet by Distribution channel
  • 2.1.3. Desmoid Tumors Market Snippet by Country
  • 2.1.4. Desmoid Tumors Market Snippet by Region
• 2.2. Competitive Insights

3. Desmoid Tumors Key Market Trends

• 3.1. Desmoid Tumors Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Desmoid Tumors Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Desmoid Tumors Market Opportunities
• 3.4. Desmoid Tumors Market Future Trends

4. Desmoid Tumors Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Desmoid Tumors Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Desmoid Tumors Market Landscape

• 6.1. Desmoid Tumors Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Desmoid Tumors Market - By Drug Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
  • 7.1.2. Non-steroidal anti-inflammatory drugs(NSAIDs)
  • 7.1.3. Chemotherapy
  • 7.1.4. Targeted Therapy
  • 7.1.5. Hormone Therapy
  • 7.1.6. Others

8. Desmoid Tumors Market - By Distribution channel

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Distribution channel, 2024 & 2032 (%)
  • 8.1.2. Hospital Pharmacies
  • 8.1.3. Retail Pharmacies
  • 8.1.4. Online Pharmacies

9. Desmoid Tumors Market- By Geography

• 9.1. Introduction
  • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 9.2. North America
  • 9.2.1. Overview
  • 9.2.2. Desmoid Tumors Key Manufacturers in North America
  • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 9.2.5. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.2.6. U.S.
    • 9.2.6.1. Overview
    • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.2.6.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.2.6.4. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.2.7. Canada
    • 9.2.7.1. Overview
    • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.2.7.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.2.7.4. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
• 9.3. Europe
  • 9.3.1. Overview
  • 9.3.2. Desmoid Tumors Key Manufacturers in Europe
  • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 9.3.5. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.6. Germany
    • 9.3.6.1. Overview
    • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.6.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.6.4. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.7. UK
    • 9.3.7.1. Overview
    • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.7.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.7.4. UK Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.8. France
    • 9.3.8.1. Overview
    • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.8.4. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.9. Italy
    • 9.3.9.1. Overview
    • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.9.4. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.10. Spain
    • 9.3.10.1. Overview
    • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.10.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.10.4. Spain Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.11. The Netherlands
    • 9.3.11.1. Overview
    • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.11.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.11.4. The Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.12. Sweden
    • 9.3.12.1. Overview
    • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.12.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.12.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.13. Russia
    • 9.3.13.1. Overview
    • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.13.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.14. Poland
    • 9.3.14.1. Overview
    • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.14.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3.15. Rest of Europe
    • 9.3.15.1. Overview
    • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.15.4. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
• 9.4. Asia Pacific (APAC)
  • 9.4.1. Overview
  • 9.4.2. Desmoid Tumors Key Manufacturers in Asia Pacific
  • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 9.4.5. APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.6. China
    • 9.4.6.1. Overview
    • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.6.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.6.4. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.7. India
    • 9.4.7.1. Overview
    • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.7.4. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.8. Japan
    • 9.4.8.1. Overview
    • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.8.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.8.4. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.9. South Korea
    • 9.4.9.1. Overview
    • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.9.4. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.10. Australia
    • 9.4.10.1. Overview
    • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.10.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.10.4. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.11. Indonesia
    • 9.4.11.1. Overview
    • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.11.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.11.4. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.12. Thailand
    • 9.4.12.1. Overview
    • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.12.4. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.13. Philippines
    • 9.4.13.1. Overview
    • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.13.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.13.4. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4.14. Rest of APAC
    • 9.4.14.1. Overview
    • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
• 9.5. Latin America (LATAM)
  • 9.5.1. Overview
  • 9.5.2. Desmoid Tumors Key Manufacturers in Latin America
  • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 9.5.5. LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5.6. Brazil
    • 9.5.6.1. Overview
    • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.6.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.6.4. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5.7. Mexico
    • 9.5.7.1. Overview
    • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.7.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.7.4. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5.8. Argentina
    • 9.5.8.1. Overview
    • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.8.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.8.4. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5.9. Colombia
    • 9.5.9.1. Overview
    • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.9.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.9.4. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5.10. Rest of LATAM
    • 9.5.10.1. Overview
    • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
• 9.6. Middle East and Africa (MEA)
  • 9.6.1. Overview
  • 9.6.2. Desmoid Tumors Key Manufacturers in Middle East and Africa
  • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 9.6.5. MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.6. Saudi Arabia
    • 9.6.6.1. Overview
    • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.7. UAE
    • 9.6.7.1. Overview
    • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.7.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.7.4. UAE Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.8. Israel
    • 9.6.8.1. Overview
    • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.8.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.8.4. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.9. Turkey
    • 9.6.9.1. Overview
    • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.9.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.9.4. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.10. Algeria
    • 9.6.10.1. Overview
    • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.10.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.10.4. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.11. Egypt
    • 9.6.11.1. Overview
    • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.11.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.11.4. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6.12. Rest of MEA
    • 9.6.12.1. Overview
    • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Desmoid Tumors Industry

• 10.1. Competitive Benchmarking
  • 10.1.1. Competitive Dashboard
  • 10.1.2. Competitive Positioning
• 10.2. Company Profiles
  • 10.2.1. Horizon Therapeutics Plc
  • 10.2.2. Strides Pharma Science Limited
  • 10.2.3. Teva Pharmaceutical Industries Ltd
  • 10.2.4. Amneal Pharmaceuticals LLC
  • 10.2.5. Hikma Pharmaceuticals PLC
  • 10.2.6. Natco Pharma Ltd
  • 10.2.7. Lupin, Zydus Lifesciences
  • 10.2.8. Mylan N.V.
  • 10.2.9. Assertio Holdings, Inc.
  • 10.2.10. Mayne Pharma Group Limited
  • 10.2.11. Alembic Pharmaceuticals Limited, Aprazer
  • 10.2.12. Ayala Pharmaceuticals
  • 10.2.13. SpringWorks Therapeutics, Inc
  • 10.2.14. Iterion Therapeutics
  • 10.2.15. Novartis AG
  • 10.2.16. Apotex Inc.
  • 10.2.17. Bayer AG
  • 10.2.18. Sun Pharmaceutical Industries Ltd
  • 10.2.19. Dr. Reddy's Laboratories Ltd
  • 10.2.20. Endo International plc
  • 10.2.21. Abbott
  • 10.2.22. Getwell Pharmaceuticals
  • 10.2.23. Others

11. 360 Degree AnalystView

12. Appendix

• 12.1. Research Methodology
• 12.2. References
• 12.3. Abbreviations
• 12.4. Disclaimer
• 12.5. Contact Us